IRF4 promotes cell proliferation by JNK pathway in multiple myeloma

被引:0
|
作者
Sensen Zhang
Jiaren Xu
Shuang Wu
Rong Wang
Xiaoyan Qu
Wenjun Yu
Jiangyong Li
Lijuan Chen
机构
[1] The First Affiliated Hospital of Nanjing Medical University,Department of Hematology
[2] Jiangsu Province Hospital,undefined
[3] Jiangsu Province Institute of Geriatrics,undefined
来源
Medical Oncology | 2013年 / 30卷
关键词
IRF4; Myeloma; JNK pathway;
D O I
暂无
中图分类号
学科分类号
摘要
Interferon regulatory factor 4 (IRF4) is a member of the interferon regulatory family, which plays an important role in many lymphoid and myeloid malignancies. In the current study, using immunohistochemical staining, we found that IRF4 only expressed in plasma cells in bone marrow biopsy samples of multiple myeloma. IRF4-positive patients displayed increased disease stage (Durie–Salmon stage, p = 0.026; and International Staging System, p = 0.005). Silencing IRF4 in myeloma cell lines could inhibit myeloma cells proliferation and induce myeloma cell apoptosis, partly by JNK/Jun pathway. These results demonstrate that IRF4 plays important roles in myelomagenesis and disease progression.
引用
收藏
相关论文
共 50 条
  • [21] The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival
    Pasquale L. Fedele
    Yang Liao
    Jia-nan Gong
    Yuan Yao
    Mark F. van Delft
    Michael S. Y. Low
    Lin Tai
    Marco J. Herold
    Jacob T. Jackson
    Charis E. Teh
    Tania Tan
    Lorraine A. O’Reilly
    Julie Tellier
    George Grigoriadis
    David C. S. Huang
    Wei Shi
    Stephen L. Nutt
    Simon N. Willis
    Leukemia, 2021, 35 : 2114 - 2118
  • [22] Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma
    D Heintel
    N Zojer
    M Schreder
    K Strasser-Weippl
    B Kainz
    M Vesely
    H Gisslinger
    J Drach
    A Gaiger
    U Jäger
    H Ludwig
    Leukemia, 2008, 22 : 441 - 445
  • [23] TREATMENT WITH LENALIDOMIDE OVERCOMES THE POOR PREDICTIVE INFLUENCE OF HIGH IRF4 IN PATIENTS WITH MULTIPLE MYELOMA
    Heintel, D.
    Schreder, M.
    Bolomsky, A.
    Hilgarth, B.
    Zojer, N.
    Gisslinger, H.
    Ludwig, H.
    Jaeger, U.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 144 - 145
  • [24] Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma
    Heintel, D.
    Zojer, N.
    Schreder, M.
    Strasser-Weippl, K.
    Kainz, B.
    Vesely, M.
    Gisslinger, H.
    Drach, J.
    Gaiger, A.
    Jaeger, U.
    Ludwig, H.
    LEUKEMIA, 2008, 22 (02) : 441 - 445
  • [25] Interferon Regulatory Factor 4 (IRF4) Promotes Lipopolysaccharide-Induced Colonic Mucosal Epithelial Cell Proliferation by Regulating Macrophage Polarization
    Hu, Lin
    Li, Song
    Li, Honglang
    Lai, Bin
    Wen, Huabin
    EUROPEAN SURGICAL RESEARCH, 2023, 63 (04) : 257 - 268
  • [26] EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma
    Ding, Linlin
    Shen, Yaodong
    Ni, Jing
    Ou, Yiqing
    Ou, Yangyu
    Liu, Hong
    TUMOR BIOLOGY, 2017, 39 (03)
  • [27] Cereblon Binding IMiD Small Molecules Mediate Myeloma Cell Death Via IRF4
    Zhu, Yuan Xiao
    Shi, Chang-Xin
    Bruins, Laura
    Kortuem, Klaus Martin
    Schmidt, Jessica
    Chang, Xiu-Bao
    Braggio, Esteban
    Bergsagel, Leif
    Stewart, Keith
    BLOOD, 2012, 120 (21)
  • [28] Aberrant activation of the WNT signaling pathway promotes proliferation in multiple myeloma
    Pals, S
    Derksen, P
    Tjin, E
    Meijer, H
    Klok, M
    MacGillavry, H
    Oers, M
    van der Neut, R
    Bloem, A
    Lokhorst, H
    Clevers, H
    Nusse, R
    Spaargaren, M
    ANNALS OF ONCOLOGY, 2005, 16 : 86 - 86
  • [29] Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma
    Zhang, Jing-Zan
    Zhang, Lin
    Ding, Xin
    Wu, Min
    Zhang, De-Jie
    Wu, Yujie
    Liu, Mingyao
    Li, Chen-Chen
    Yi, Zhengfang
    Qiu, Wen-Wei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 285
  • [30] p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma
    McKeown, Michael R.
    Giorgetti, Giulia
    Lenoir, Walter F.
    Kobylarz, Marek J.
    Hopkins, Tamara D.
    Glore, Wayne L.
    Shum, Michelle G.
    Calderon, Yare
    Mori, Kameron R.
    Gao, Hua
    Carvajal, Luis A.
    Obholzer, Nikolaus D.
    Trotter, Benjamin W.
    Dinsmore, Christopher D.
    Munshi, Nikhil C.
    Rahl, Peter B.
    Fulciniti, Mariateresa
    Lin, Charles Y.
    CANCER RESEARCH, 2024, 84 (06)